Phase 3 interim data for RYZ101, the lead asset from Bristol Myers Squibb’s $4.1 billion RayzeBio deal, meet the primary endpoint.
Feature|Videos|April 10, 2025
Fueling Innovation Through Client Centricity
Author(s)Rentschler Biopharma
Christiane Bardroff, Chief Operating Officer and Patrick Meyer Global Head of Business Development—both at Rentschler Biopharma SE—share their insights into the company’s client-centric approach.
Rentschler Biopharma's client-first approach, major investments in US and German sites, and the launch of Rentschler Development Services are positioning the company to best offer flexible, tailored solutions. Watch this video to learn more about:
- How Rentschler Biopharma’s client-centric approach drives innovation in biologics development and manufacturing.
- The capabilities at Rentschler’s state-of-the-art biologics facility in Milford, MA.
- Customized services and solutions available at the Milford, MA site.
Related to this article
Efzimfotase alfa missed significance on the six-minute walk test in adolescents and adults, while the FDA review of the therapy proceeds toward 2027.
Odyssey's 146-patient phase 2a trial will pair OD-001 with vedolizumab, targeting both innate and adaptive immune drivers of ulcerative colitis.
MT027, T-MAXIMUM's B7-H3 CAR-T therapy, earns a second FDA-cleared phase 2 trial, now testing lung and breast cancer brain metastases.
New clinical data highlight improved disease control, reduced eye bulging, and weight-loss benefits, potentially broadening options for patients with unmet needs.
Antisense oligonucleotides are reshaping drug design, from RNase H gapmers to inhaled delivery; this FAQ explains how they work and why trials still fail.
Bristol Myers Squibb's Nathan Pennell explains how the MRD endpoint supports accelerated approval in multiple myeloma without changing how clinicians monitor patients.
Once-weekly amylin analog petrelintide produced up to 9.2% weight loss at 28 weeks in adults with obesity and type 2 diabetes, Zealand Pharma reports.